Here’s a handful of cheap stocks that could turn red hot in 2025, according to analysts

Cheap stocks represent an opportunity to supercharge our portfolios. Dr James Fox details several deemed undervalued by analysts.

| More on:
Young Asian woman holding a cup of takeaway coffee and folders containing paperwork, on her way into the office

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Major institutions, brokerages, and banks issue price targets for companies within their surveillance. And while this isn’t the only way to identify cheap stocks, retail investors like us can learn a lot from these price targets. After all, it can be wise to use other people’s research as a starting point at least.

Standout undervalued stocks

Some of the cheapest stocks, according to analysts, tend to be early stage biotech or pharma companies. For example, micro cap Tempest Therapeutics trades 2,200% below its share price target. However, I’d be wary not to be drawn in by these figures as these stocks are typically only covered by one or two analysts. The reality with early stage biotechs is they are more likely to crash and burn than they are to be the next big winner — and that’s not reflected in the price target.

So, ignoring those anomalies, here are some companies that stand out:

StockDiscount to average share price target
Abercrombie & Fitch55.5%
Currys35%
Microstrategy65.9%
Scorpio Tankers78%
VinFast55.9%

Just a starting point

These share price targets should be seen as a starting point. It’s worth recognising that analysts don’t update their outlooks all the time, and as such, there can be something of a lag. However, if I were looking to make investments in these companies, I’d certainly find this consensus data encouraging.

It may also pay an investor to pick holes in these high price targets. For example, will Currys’ shareholders look to take profits after the recent rally or are tanker stocks the right place to be as oil demand pushes lower?

Focusing in on Scorpio Tankers

Having said this, one stock investors may consider looking more closely at is Scorpio Tankers (NYSE:STNG). After retreating from previous highs, the refined petroleum shipper now trades at attractive valuations, with a trailing price-to-earnings (P/E) ratio of 3.62 as of January 2025 — 56% below its decade-long average. Analysts project modest P/E expansions to 4.75 times for FY 2024 and 6.3 times in 2025 based on consensus estimates, suggesting room for revaluation if operational strengths persist.

The company boasts a 20% return on capital employed (ROCE), outperforming industry peers by nearly 70%, while strategically expanding its market position through a recent $131.5m stake increase in VLCC operator DHT Holdings. However, there are some risks, including falling hydrocarbon demand in the near term, which could be exacerbated by climate policies.

Offsetting these concerns, Scorpio’s modern fleet (average age 8.6 years) positions it to capitalise on tightening tanker supply, with shipyard backlogs limiting new vessel deliveries. Scorpio’s fuel-efficient LR2 tankers are better equipped than most peers for emissions regulations, meaning it‘s also better positioned to bid for prime contracts. Last time I checked, I couldn’t buy this stock through my brokerage, but it’s one I’m watching closely nonetheless.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

2 UK shares that could soar if interest rates sprint lower!

The Bank of England's latest meeting has fed speculation of swingeing interest rate cuts. I think these UK shares could…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

My favourite FTSE dividend stock just jumped 17%! So why am I sad?

This investor has mixed feelings today as a quality dividend stock from the FTSE 250 surged higher in his portfolio.…

Read more »

Investing Articles

Here’s why AstraZeneca stock jumped nearly 6% in the FTSE 100 today

FTSE 100 heavyweight AstraZeneca helped propel the blue-chip index to a record high today. Here's what investors were cheering.

Read more »

Closeup of "interest rates" text in a newspaper
Investing Articles

Interest rates fall again! Here are 3 FTSE dividend growth shares to consider buying

As interest on cash savings becomes increasingly less attractive, Paul Summers has been looking at dividend growth shares for passive…

Read more »

Investing Articles

Up 10% today, I think this FTSE 250 growth share could continue to surge!

Babcock International's flying after upgrading its full-year forecasts. I think the FTSE 250 defence share might just be getting started.

Read more »

Investing Articles

The AstraZeneca share price jumps 5% on today’s strong results – but is it too expensive?

Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's biggest company…

Read more »

Investing Articles

Is this my chance to buy Alphabet shares?

A big step up in AI spending at Google has investors nervous, but has it created an opportunity to buy…

Read more »

Senior woman potting plant in garden at home
Investing Articles

£10k in savings? Here’s how an investor could aim for a monthly second income of £1,200

Mark David Hartley considers how investors could build towards an early retirement plan with a second income from a portfolio…

Read more »